Morning Trend | INNOCARE frequently experiences capital fluctuations, is bottom-fishing about to begin?

On January 21, INNOCARE (9969.HK) experienced low-level fluctuations throughout the day, with occasional short-term capital movements but overall main funds did not fully return. The MACD death cross continues, and the weak pattern intensifies the long-short game, making the chips unusually sensitive. The company's recent news front is calm, with no major new projects, collaborations, or significant clinical progress announced. The entire biopharmaceutical sector has noticeably cooled down, with rapid internal capital rotation, and short-term hotspots have shifted towards varieties with policy expectations, putting relative pressure on INNOCARE's liquidity. The main focus in the industry is on the clinical progress of new drugs, and investors are generally waiting for the next major positive developments. Technically, CNY 0.16 has become a phase support level of market concern. If it falls below this level, the weak decline may be amplified, and caution is needed to avoid a stampede effect. The high volatility during the day comes from short-term speculative funds, and a trend for bullish positions has not yet formed. Operational advice: Pay attention to new industry news, new drug batches, and sector flows. For right-side traders, maintain a defensive posture until there is a significant increase in volume. The atmosphere for short-term trading is strong, and during this unclear trend phase, safety should come first, making heavy participation inadvisable